Journal: AMB Express

Article Title: Integrative mendelian randomization and multi-omics analysis reveal a gut microbiota-metabolite-CXCL10 axis in breast cancer

doi: 10.1186/s13568-025-01989-0

Figure Lengend Snippet: Validation of the gut microbiota–CXCL10–breast cancer axis. A Colocalization of CXCL10 and CXCR3 in breast cancer cells (Co-IP assay). B qRT-PCR analysis of CXCL10 expression after Enterococcus faecalis or Lariciresinol treatment. C ELISA quantification of secreted CXCL10 after Enterococcus faecalis or Lariciresinol treatment. D Knockdown efficiency of CXCL10 in breast cancer cells (MDA-MB-231 and MCF-7) verified by qPCR. E CCK-8 assay for cell proliferation under different treatments

Article Snippet: After blocking with 10% skim milk for 1 h, membranes were incubated overnight at 4°C with primary antibodies against CXCR3 (1:1000, 26,756–1-AP, Proteintech, USA) and CXCL10 (1:1000, 10,937–1-AP, Proteintech, USA), followed by HRP-conjugated Goat Anti-Rabbit secondary antibody (1:5000, Beyotime, A0208).

Techniques: Biomarker Discovery, Co-Immunoprecipitation Assay, Quantitative RT-PCR, Expressing, Enzyme-linked Immunosorbent Assay, Knockdown, CCK-8 Assay